| https://www.grants.gov/web/grants/search-grants.html?keywords=Coronavirus | 
        
            | Updated: 10/23/2020 (all new/revised opportunities listed first) |   |   | 
        
            | Agency | Opp Number | Name of solicitation | Application Due Date | Notes | 
        
            | NEW/REVISED |   |   |   |   | 
        
            | BARDA | BARDA-BAA | Advanced development and licensure of COVID-19 diagnostics, vaccines or medicines, such as therapeutics or antivirals. | 4/30/2020 | Added due date | 
        
            | CDC | 75D301-20-R-67897 | Broad Agency Announcement (BAA) Applied Research to Address The Coronavirus (COVID-19) Emerging Public Health Emergency | 03/25/2020 | Immediate call for White papers.  | 
        
            | NIAID | NIAID-BAA2020-1 | 2020 NIAID Omnibus Broad Agency Announcement | 04/09/2020 | Extended deadlines in specific areas only | 
        
            | NIAID | NOT-AI-20-030 | Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) | ---------- | Rolling deadlines | 
        
            | NIAID | RFA-AI-20-028 | Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) | 06/29/2020 | Mandatory LOI due 05/29/2020 | 
        
            | NIAID | PAR-18-781 | Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed) | 09/09/2020 |   | 
        
            | NIDA | NOT-DA-20-047 | Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus | ------- | Supplement to existing awards.  Rolling deadlines. Especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. | 
        
            | NHLBI | NOT-HL-20-757 | Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) | ------ | Supplement to existing awards.  Rolling deadlines. Topics of specific interest to NHLBI include SARS-CoV-2 host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals. | 
        
            | NIA NIAID NIDDK NIDA NIMH NIEHS NICHD NIAAA | PA-18-935 | Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) | ------ | Continuous submission. Earliest start dates may vary by awarding IC. See the Urgent Guide Notices for any applicable Application Due Dates. | 
        
            | NIAID NIA | PAR-20-139 | Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) | 05/13/2020 |   | 
        
            | NIHR (UK) | Travel Funds | Travel and subsistence funding to support delivery of technical expertise in the global response to Covid-19. | 05/30/2020 | Continuous submission. For UK collaborations only     | 
        
            |   |   |   |   |   | 
        
            | Previous Postings  |   |   |   |   | 
        
            | HHS-CDC-OSTLTS | CDC-RFA-OT18-18020202SUPP20 | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nations Health | 04/02/2020 |   | 
        
            | DOE | Dear Colleague Letter | DOE mission complements the efforts of the National Institutes of Health, the Department of Defense, and other Federal partners by helping to understand the scientific phenomena contributing to COVID-19, from the structure of the SARS-CoV-2 virus, which causes the disease, to models that can mimic its spread. | Responses accepted starting March 18, 2020 |   | 
        
            | HHS-CDC-CGH | CDC-RFA-GH20-2113 | Expanding Efforts and Strategies to Protect and Improve Public Health inVietnam | 5/11/2020 |   | 
        
            | HHS-CDC-CGH | CDC-RFA-GH20-2125 | Enhancing Global Health Security: Expanding Efforts and Strategies to Protect and Improve Public Health in the Democratic Republic of the Congo (DRC) | 5/12/2020 |   | 
        
            | HHS-CDC-OSTLTS* | CDC-RFA-OT18-18020202SUPP20 | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nations Health | 4/2/2020 |   | 
        
            | HHS-CDC-CGH | CDC-RFA-GH20-2124 | Improving Health Security and Building International Health Regulations core capacities in the Republic of Uganda | 5/12/2020 |   | 
        
            | HHS-CDC-CGH | CDC-RFA-GH20-2115 | Expanding Efforts and Strategies to Protect and Improve Public Health in Kenya | 5/11/2020 |   | 
        
            | HHS-CDC-CGH | CDC-RFA-GH20-2118 | Global Health Security through Strengthened Community Based Surveillance | 5/11/2020 |   | 
        
            | HHS-CDC-CGH | CDC-RFA-GH20-2131 | Strengthening Regional Field Epidemiology Training Program (FETP) Networks | 5/4/2020 |   | 
        
            | HHS-CDC-CGH | CDC-RFA-GH20-2119 | Global Health Security Partner Enhancement : Expanding Efforts to Improve Surveillance and Laboratory Data Interoperability | 5/4/2020 |   | 
        
            | DHHS/CDC | CDC-RFA-OT18-18020202SUPP20 | Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nations Health | 3/20/2020 |   | 
        
            | USAID | 7200AA20RFA00007 | STOP Spillover | N/A |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2093 | Protecting and Improving Public Health Globally: Building and Strengthening Public Health Impact, Health Systems, Capacity Building, and Health Security in Cote d’Ivoire | 04/07/20 11:59 ET |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2094 | Advancing Ethiopia's Capacity for Laboratory, Workforce Development, Surveillance, and Emergency Management to meet International Health Regulations requirements | 04/07/2020 11:59 ET |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2095 | Strengthening Laboratory Systems to Establish Routine Laboratory based surveillance for Priority Infectious Diseases in India | 04/27/2020 11:59 ET |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2108 | Strengthening Global Field Epidemiology Training Program (FETP) Network | 04/27/2020 11:59 ET |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2107 | Building Capacity for National Public Health Institutes | 5/4/2020 |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2109 | Global Health Security Partnerships: Expanding and Improving Public Health Laboratory Strategies and Systems. | 5/4/2020 |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2122 | Strengthening Sustainability of Global Health Security Objectives in Sierra Leone | 5/4/2020 |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2092 | Global Health Security Partnership Engagement: Expanding Efforts and Strategies to Protect and Improve Public Health in Cameroon | 4/7/2020 |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2126 | Strengthening Global Health Security by implementation of the International Health Regulations (IHR) (2005) and the Global Health Security Agenda in Nigeria | 4/27/2020 |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2110 | Enhancing Global Health Security: Expanding Efforts and Strategies to Protect and Improve Public Health Globally | 4/27/2020 |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2091 | Accelerating Sustainability of Public Health Systems in India to Prevent, Detect, and Respond to Infectious Disease Outbreaks and Other Public Health Emergencies | 4/27/2020 |   | 
        
            | DHHS/CDC | CDC-RFA-GH20-2101 | Tanzania Global Health Security Partner Engagement: Advancing Efforts and Strategies to Protect and Improve Public Health | 4/27/2020 |   | 
        
            | HHS-NIH11 | RFA-AI-20-009 | Three-Dimensional (3D) Human Biomimetics for Infectious Diseases (U19 Clinical Trial Not Allowed) | 5/29/2020 |   | 
        
            | HHS-CDC-CGH | CDC-RFA-GH20-2095 | Strengthening Laboratory Systems to Establish Routine Laboratory based surveillance for Priority Infectious Diseases in India | 4/27/2020 |   | 
        
            | HHS-NIH11 | PAR-20-108 | International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) | 8/19/2022 |   | 
        
            | NIH Funding |   |   |   |   | 
        
            | NIH/NIAID/NIA | PAR-20-139 | Invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. | 05/13/2020 |   | 
        
            | NIH/NIAID/ NIGMS | NOT-AI-20-030 | Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) | Immediate |   | 
        
            | NIH/NIAID | RFA-AI-20-021 | Vaccine and Treatment Evaluation Units (VTEUs): Enhancing Capability and Capacity (UM1 Clinical Trial Required) | 04/14/2020 |   | 
        
            | NIH/NIAID | RFA-AI-20-009 | Three-Dimensional (3D) Human Biomimetics for Infectious Diseases (U19 Clinical Trial Not Allowed) | 05/29/2020 |   | 
        
            | NIH/NIAID | RFA-AI-20-003 | Partnerships for the Development of Universal Influenza Vaccines (R21/R33 Clinical Trial Not Allowed) | 06/02/2020 |   | 
        
            | NIH/NIAID | RFA-AI-20-008 | Multidisciplinary Studies to Improve Understanding of Influenza Transmission (U19 Clinical Trial Optional) | 06/23/2020 |   | 
        
            | NIH/Multiple Institutes | PA-18-591 | Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) | Contact Program Officer |   | 
        
            | NIH/Fogarty International Center |   | Ecology and Evolution of Infectious Diseases Initiative (EEID) | 11/18/2020 |   | 
        
            | OTHER FEDERAL AGENCIES |   |   |   | 
        
            | NSF | Letter to Researchers | To conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge. | Immediate  |   | 
        
            | PRIVATE FUNDING |   |   |   | 
        
            | Bill & Melinda Gates Foundation, Wellcome, and Mastercard COVID-19 Therapeutics Accelerator |   | $125 million to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and  scaling-up treatments. |   |   |